Skip to Content
Morningstar

Spero Therapeutics Inc SPRO

Morningstar Rating
Unlock
Stock XNAS Rating as of
$1.46 +0.03 (1.94%)
View Full Chart
As of Delayed Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
SPRO is trading at a 42% discount.
Price
$1.44
Fair Value
$9.34
Uncertainty
Extreme
1-Star Price
$5.33
5-Star Price
$1.94
Economic Moat
Mrw
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SPRO is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$1.43
Day Range
$1.42–1.51
52-Week Range
$0.99–2.00
Bid/Ask
$1.45 / $1.47
Market Cap
$78.57 Mil
Volume/Avg
115,087 / 325,545

Key Statistics

Price/Earnings (Normalized)
2.86
Price/Sales
0.78
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
46
Website
https://www.sperotherapeutics.com

Comparables

Valuation

View More
Metric
SPRO
AVIR
ENTA
Price/Earnings (Normalized)
 2.86——
Price/Book Value
 0.710.561.38
Price/Sales
 0.78—3.57
Price/Cash Flow
 2.03——
Price/Earnings
SPRO
AVIR
ENTA

Financial Strength

Metric
SPRO
AVIR
ENTA
Quick Ratio
 3.4217.866.04
Current Ratio
 3.5318.246.25
Interest Coverage
 ———
Quick Ratio
SPRO
AVIR
ENTA

Profitability

Metric
SPRO
AVIR
ENTA
Return on Assets (Normalized)
 31.53%−15.46%−27.96%
Return on Equity (Normalized)
 55.40%−16.16%−47.34%
Return on Invested Capital (Normalized)
 46.45%−19.92%−44.45%
Return on Assets
SPRO
AVIR
ENTA
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVctkgfgbctQlr$554.7 Bil
VRTX
Vertex Pharmaceuticals IncPnytqqfjhJnzsj$103.6 Bil
REGN
Regeneron Pharmaceuticals IncHjtbvwydLzsjhr$97.8 Bil
MRNA
Moderna IncCrgrkcgnXjgvt$38.8 Bil
ARGX
argenx SE ADRZzffrtdRln$22.0 Bil
BNTX
BioNTech SE ADRRlzrpdpGgkn$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncNnvdkkwkXwhbmd$18.2 Bil
BMRN
Biomarin Pharmaceutical IncZqbzgdxGxtdh$17.3 Bil
RPRX
Royalty Pharma PLC Class AXwskntkjYrlfm$12.5 Bil
INCY
Incyte CorpPvwvmytpnXpbgnc$11.5 Bil

Sponsor Center